Literature DB >> 7593628

Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.

J C Magee1, B H Collins, R C Harland, B J Lindman, R R Bollinger, M M Frank, J L Platt.   

Abstract

Immunoglobulins regulate the complement system by activating complement on foreign surfaces and diverting reactive complement proteins away from autologous cell surfaces. Based on this model, we explored the ability of Ig to balance complement activation versus control in a pig-to-primate cardiac xenotransplantation model in which the binding of xenoreactive antibodies of the recipient to graft blood vessels and the activation of complement cause hyperacute rejection. Human IgG added to human serum caused a dose-dependent decrease in deposition of iC3b, cytotoxicity, and heparan sulfate release when the serum was incubated with porcine endothelial cells. This decrease was not caused by alteration in antibody binding or consumption of complement but presumably reflected decreased formation of C3 convertase on the endothelial cells. Infusion of purified human IgG into nonhuman primates prevented hyperacute rejection of porcine hearts transplanted into the primates. As expected, the transplants contained deposits of recipient Ig and C1q but not other complement components. The inhibition of complement on endothelial cell surfaces and in the xenotransplantation model supports the idea that IgG regulates the classical complement pathway and supports therapeutic use of that agent in humoral-mediated disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593628      PMCID: PMC185892          DOI: 10.1172/JCI118297

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

Review 1.  The classical complement pathway: activation and regulation of the first complement component.

Authors:  N R Cooper
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

Review 2.  The role of antibody in the activation of the alternative complement pathway.

Authors:  W D Ratnoff; D T Fearon; K F Austen
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Retardation of fading and enhancement of intensity of immunofluorescence by p-phenylenediamine.

Authors:  J L Platt; A F Michael
Journal:  J Histochem Cytochem       Date:  1983-06       Impact factor: 2.479

4.  Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.

Authors:  F D Moore; K F Austen; D T Fearon
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

5.  Identification of porcine endothelial cell membrane antigens recognized by human xenoreactive natural antibodies.

Authors:  Z E Holzknecht; J L Platt
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

6.  Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury.

Authors:  K R McCurry; D L Kooyman; C G Alvarado; A H Cotterell; M J Martin; J S Logan; J L Platt
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

7.  Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease.

Authors:  R J Falk; A P Dalmasso; Y Kim; C H Tsai; J I Scheinman; H Gewurz; A F Michael
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

8.  Immune cell populations in cutaneous delayed-type hypersensitivity.

Authors:  J L Platt; B W Grant; A A Eddy; A F Michael
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

9.  A unique natural human IgG antibody with anti-alpha-galactosyl specificity.

Authors:  U Galili; E A Rachmilewitz; A Peleg; I Flechner
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

Authors:  L F Fries; T A Gaither; C H Hammer; M M Frank
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

2.  Fate of antigen in xenotransplantation: implications for acute vascular rejection and accommodation.

Authors:  W Parker; Z E Holzknecht; A Song; B A Blocher; M Bustos; K J Reissner; M L Everett; J L Platt
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 3.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

Review 4.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  Sensitized renal transplant recipients: current protocols and future directions.

Authors:  James Gloor; Mark D Stegall
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

6.  The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants.

Authors:  S S Lin; B C Weidner; G W Byrne; L E Diamond; J H Lawson; C W Hoopes; L J Daniels; C W Daggett; W Parker; R C Harland; R D Davis; R R Bollinger; J S Logan; J L Platt
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 7.  Non-canonical B cell functions in transplantation.

Authors:  Jeffrey L Platt; Marilia Cascalho
Journal:  Hum Immunol       Date:  2019-04-10       Impact factor: 2.850

8.  Complement activation by human IgG antibodies to galactose-α-1,3-galactose.

Authors:  Jens Magnus Bernth Jensen; Nick Stub Laursen; Rasmus Kjeldsen Jensen; Gregers Rom Andersen; Jens Christian Jensenius; Uffe B Skov Sørensen; Steffen Thiel
Journal:  Immunology       Date:  2020-07-14       Impact factor: 7.397

Review 9.  Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation.

Authors:  Stanley C Jordan; Ashley Vo; Dolly Tyan; Mieko Toyota
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

10.  Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient.

Authors:  Ashim Aggarwal; Joseph Pyle; John Hamilton; Geetha Bhat
Journal:  Tex Heart Inst J       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.